Human T-cell leukemia (or lymphotropic) virus type II (HTLV-II) was isolated from eight HTLVseropositive patients, six of whom were also infected with human immunodeficiency virus, by cocultivation of peripheral blood mononuclear cells (PBMCs) with BJAB, a continuous B-cell line. Restriction endonuclease mapping of the proviruses demonstrated consistent differences among isolates, and two distinct physical map patterns were observed. The results suggest the existence of two closely related molecular subtypes of HTLV-II, which are tentatively designated HTLV-IIa and HTLV-IIb. This finding was supported by preliminary nucleotide sequence analysis of the env gene region encoding the transmembrane glycoprotein gp2l, which showed consistent differences between the two proposed virus subtypes. Exploitation of differences in restriction endonuclease sites allowed polymerase chain reaction amplification to detect and differentiate the two subtypes in fresh PBMCs of HTLV-seropositive intravenous drug abusers (IVDAs). The results of these studies confirm that HTLV-II infection is the prominent HTLV infection in seropositive IVDAs and also show that infection with both subtypes occurs.
Human T-cell leukemia (or lymphotropic) virus type I (HTLV-I) and HTLV-II are genetically related members of a group of retroviruses sharing a tropism for T lymphocytes and an association with rare lymphoproliferative diseases (34, 42) . HTLV-I infection is endemic in well-defined geographic areas and is associated with adult T-cell leukemia, a malignancy of mature T lymphocytes (10, 24, 27, 28, 32, 43) , and with a chronic encephalomyelopathy known both as tropical spastic paraparesis and HTLV-I-associated myelopathy (6, 25) . In contrast, HTLV-II infection has not been definitely associated with any human disease. However, isolation of the virus from two patients with very rare T-cell variants of hairy cell leukemia (5, 12, 15, 36) , one of whom also had a coexisting CD8+ proliferative process (35) , does suggest a potential role for the virus in lymphoproliferative disorders.
Although the true extent of infection by HTLV-II remains unknown, serological studies (33, 41) , subsequently confirmed by DNA amplification using the polymerase chain reaction (PCR) (4, 9, 16, 20) , have shown that intravenous drug abusers (IVDAs) are at increased risk for infection. More recently, similar studies have suggested that the virus may be endemic in New World indigenous populations (11, 12, 19, 31) . Although the methods employed in these studies have allowed the identification of HTLV-II infection, relatively few attempts have been made to isolate and characterize the viruses involved. Such studies have long been needed to obtain a better understanding of the biology and to investigate possible genetic variation in this group of viruses. Recently we have described the use of cocultivation of peripheral blood mononuclear cells (PBMCs) with BJAB, a * Corresponding author.
continuous Epstein-Barr virus-negative B-cell line to selectively isolate HTLV-II from IVDAs who were concomitantly infected with human immunodeficiency virus (HIV) (9) . Preliminary studies using Southern hybridization analysis on two isolates suggested that there may be some genetic heterogeneity in the HTLV-II group of viruses. In this report we extend these findings and describe the isolation and characterization of HTLV-II from eight individuals both with and without HIV infection.
MATERIALS AND METHODS
Patient population and serological studies. All patients enrolled in this study were from the New York City area and were evaluated at North Shore University Hospital between 1984 and 1990. For virus isolation studies, six patients who were seropositive for both HIV and HTLV-I-HTLV-II and two who were seropositive for HTLV-I-HTLV-II alone were selected. All patients were shown to be HTLV-II infected by using PCR amplification methods previously described (9) . The demographic characteristics of these patients are described in the Results section (Table 1) . Twelve additional and randomly chosen HTLV-I-HTLV-II-seropositive patients, all of whom had a history of intravenous drug abuse (IVDA) and who were also HIV infected were selected for additional PCR amplification studies. Sera were screened for HIV and HTLV-I-HTLV-II antibodies by using commercially available enzyme-linked immunosorbent assays (Dupont and Cellular Products, respectively), with positive immunoreactivities being confirmed by Western immunoblot analysis. Written informed consent was obtained from each patient prior to study entry.
Virus isolation from PBMCs. Virus isolation was carried HTLV-II ISOLATES 2457 Cloning and nucleotide sequence analysis of amplified products. PCR-amplified products, using unlabelled primers, were electrophoresed on low-melting-temperature agarose gels; after ethidium bromide staining, DNA bands were excised and the agarose was melted by heating it at 70°C for 15 min. After centrifugation, DNA in supernatants was ligated to plasmid pCR1000 (Invitrogen) and used to transfect Escherichia coli (INVa F'), using conditions recommended by the manufacturer. Positive colonies were selected and grown in LB medium, and plasmids were purified by standard methods (38) . DNA sequencing with M13 reverse and forward primers was carried out by using the dideoxy chain termination method (Sequenase; United States Biochemical Corp.). At least two clones from each isolate were sequenced to ensure the reliability of the method.
Nucleotide sequence accession number. DNA sequences have been deposited in GenBank under accession number MA5226.
RESULTS
Virus isolation. In a recent study we have shown that HTLV-II could be isolated from PBMCs of IVDAs who were seropositive for both HIV and HTLV by cocultivation with BJAB, a continuous B-cell line (9) . In the present study we extend these findings and describe the isolation of HTLV-II from individuals with and without concomitant HIV infection. Eight patients, all of whom were seropositive for HTLV-I-HTLV-II, were selected; and the ages, sex, race, and possible risk factors for infection are shown in Table 1 . Six patients, five of whom had a history of IVDA, had concomitant HIV infection. Two were HIV negative; of these one had a history of IVDA, with the other having no known risk factors for HTLV infection. Cocultivation of phytohemagglutinin-and IL-2-stimulated PBMCs with BJAB cells resulted in prominent syncytium formation within 12 to 48 h (Fig. 1) . Although cell death would eventually occur, upon continued cocultivation with fresh BJAB cells the cell lines could be maintained for several months. Supernatants of cocultures had Mg2"-dependent reverse transcriptase activity (data not shown), and electron microscopy demonstrated the presence of type C particles (Fig. 1) . Thus, it appears that HTLV-II replication in BJAB cells is cytopathic, with cell-free virus production, which contrasts to the situation in vivo, in which the infection remains cell associated and presumably there is little or no virus replication.
Provirus mapping studies. Southern hybridization analysis of DNA from the cultures confirmed the presence of the HTLV-II provirus (Fig. 2) . Hybridization of chromosomal DNA digested with BamHI with the 3' probe gave the expected signal of 3.5 kb in all eight isolates. However when the 5' probe was employed, only four DNAs (isolates 1 to 4) produced the expected 4.7-kb signal defined by the two BamHI sites which have been described for HTLV-II-Mo (5, 14) . The remaining four proviruses (samples 5 to 8) had an additional BamHI site in the 5' end, with signals at 3.2 and 1.5 kb being observed. Physical maps of the eight proviruses were prepared after partial and complete digestion with single and combinations of restriction enzymes and SQuthern hybridization analysis. The results are shown in Fig. 3 . It could be demonstrated that isolates 1 to 4 and 5 to 8, respectively, had identical physical maps and that there were consistent differences between these isolates. In summary, isolates S to 8 differed from isolates 1 to 4 in that the former were all found to have an additional BamHI site in the 5' end of the provirus and did not have the expected XhoI, SacI, PstI, and BglII sites in the 5' end nor a XhoI site in the 3' end (see Fig. 5 ). Comparison of the physical maps of the isolates with those available for isolates Mo and NRA (Fig. 3) showed that isolates 1 to 4 had identical maps to that of isolate Mo. Although a detailed physical map of the NRA isolate is not available, it would appear from the published data (36) that it is similar to that of isolates 5 to 8 in that it was reported to have an additional BamHI site in the 5' end and did not contain the two XhoI sites described in the Mo isolate. The findings of consistent differences in the physical maps suggest that there may be two closely related molecular subtypes of HTLV-II, and for the purposes of further studies these were tentatively designated HTLV-IIa and HTLV-IIb.
PCR amplification. PCR amplification methods were established to allow both the identification of HTLV-II and to differentiate the two proposed subtypes with the aim of screening PBMC DNA of HTLV-I-HTLV-II-seropositive individuals. Primers were selected to amplify the gene region encoding the gp2lenv transmembrane protein, because the physical maps show that type a isolates have a XhoI site in this region, whereas type b isolates do not. Thus, XhoI digestion of amplified DNA should allow a differentiation of the two subtypes. In these experiments both primers were labelled at the 5' ends prior to amplification and the products were directly analyzed by electrophoresis and autoradiography after XhoI digestion. The results obtained are shown in Fig. 4 from amplification of the type b DNA was not digested by XAhoI. Analysis of the 12 PBMC DNAs showed that in 8, digestion of the amplified product gave the two fragments of the expected size, whereas four remained undigested. in addition to showing that all the patients have HTLV-II infection it appears that both of the proposed types are present in this population. It also appears that the incorporation of labelled primers into the type b amplified product is less than that into the type a product (Fig. 4) . The reasons for HTLV-IIA HTLV-IIB this are unclear but may reflect some divergence of sequence in the primer regions.
Nucleotide sequence analysis. To determine whether there are significant differences in nucleotide sequence between the two proposed HTLV-II subtypes, the amplified products representing the transmembrane gp2l protein gene regions were cloned and sequenced. In these studies four isolates, two representing each HTLV-II subtype (type a, isolates 1 and 3; type b, isolates 6 and 7) were analyzed. To ensure the reliability of the method, the same region of HTLV-II-Mo was also analyzed and was found to have a sequence identical to that previously published (39) . In addition, at least two clones of each amplified region of each isolate were analyzed, and no differences were noted. Figure 5 shows that both type a isolates had an identical sequence to that reported for HTLV-II-Mo. The type b isolates showed identical changes in 25 bases, suggesting a 4% divergence in nucleotide sequence. Only one base difference was noted between the two type b isolates. All changes noted appear to be point mutations, and it can be seen that the XhoI site in type b isolates is lost as a result of a single base change (C to T). Despite the relatively large number of nucleotide changes, the predicted amino acid sequence of C N N S I I L P P F S L A P V P P P A T R R R R A V P I A V CT6CAACAACTCCATTATCCTCCCCCCTTTTTCCCTC6CTCCC6TACCTCCTCC66C6ACAA6AC6CCGCC6T6CC6TTCCAATAGCAGT (ISOLATE 6) (ISOLATE 7) (8) and from a patient with hemophilia A who had received multiple blood product transfusions (14) . Although the latter isolates were not directly compared, the published physical maps of the proviruses would suggest that both were identical to the Mo isolate. Recently, we isolated and characterized HTLV-II from two IVDAs who were concomitantly infected with HIV (9) . Restriction enzyme mapping showed that whereas one isolate had an identical map to that of Mo, the second showed similarities to NRA, and the findings suggested that there may be genetic heterogeneity in the HTLV-II group of viruses.
In the present study using eight virus isolates we have confirmed that there is genetic heterogeneity, but this is restricted, and there appear to be two different but consistent physical provirus map patterns. Four The results of the present studies are too preliminary to allow a comparison of the degree of nucleotide sequence divergence occurring in HTLV-II with that in HTLV-I proviruses. In the areas of Japan, the Caribbean basin, and Africa in which HTLV-I is endemic, the upper limit of divergence between HTLV-I isolates has been estimated at 3.5%, but it is generally much lower than this (3, 13, 17, 18, 23, 29, 30) . The majority of nucleotide differences are single point mutations, and no correlation has been observed between the changes and virus pathogenicity (3, 17, 18) . In contrast, recent studies of HTLV-I isolates from newly discovered foci in Melanesia have shown up to 10% divergence in nucleotide sequence from those isolated in the historically established areas (7) . It may well be that these new isolates represent distinct molecular subtypes of HTLV-I and may have unique biological properties. By analogy with HTLV-I it can be expected that some divergence in nucleotide sequence will also be found within the two proposed subtypes of HTLV-II. Further studies will determine whether this occurs more frequently in certain gene regions and, since many of the changes appear to be point mutations, whether this will also produce restriction enzyme site polymorphism(s). Furthermore, continued analysis of new HTLV-II isolates may lead to the identification of additional subtypes with perhaps differing biological properties. If further analysis confirms significant nucleotide differences among HTLV-II isolates, this may well explain some of the inconsistent results observed in a number of PCR studies in which certain gene regions of HTLV-II could be amplified whereas others could not (4, 16) .
The present study also extends our previous observations that HTLV-II is the prominent HTLV infection in seropositive IVDAs who are concomitantly infected with HIV (9) . Employing PCR to amplify gene regions which contained differences in restriction endonuclease sites, 12 seropositive IVDAs were all shown to have HTLV-II infection, with 8 and 4 being infected with subtypes IIa and Ilb, respectively. Recently it has been reported that HTLV-II infection may be endemic in certain New World indigenous populations. Similar studies to those described here should determine whether one of the proposed subtypes occurs exclusively or predominates.
The present study may have important implications for investigations into the role of HTLV-II in human disease. At present no definite disease associations exist, but this may well be due to the small number of individuals identified with HTLV-II infection and to the relatively long latent periods expected between infection and the onset of disease. Future studies to better define this role should take into consideration potential genetic heterogeneity and possibly different biological properties of the viruses. It HTLV seropositive (9) and this is predominantly due to HTLV-II infection (4, 9, 16, 20) . Studies of homosexual males concomitantly infected with HTLV-I and HIV have suggested that they have significantly increased risk for the development of AIDS than individuals infected with HIV alone (1, 21) . Similarly, it has been suggested that mortality is higher in IVDAs with AIDS if there is concomitant HTLV infection (26) . This apparent increase in HIV pathogenicity is supported by in vitro studies that the HTLV tax gene products can activate HIV gene expression in infected T cells (2, 40) , that there is increased production of infectious HIV in cell lines mitogenically stimulated with HTLV-I (44) , and that pseudotype formation may occur which could possibly lead to an extended tropism for HIV (22) . Prospective clinical and immunological investigations in this IVDA population will allow a better understanding of such interactions and of the role of HTLV-II in human disease.
